BCL2 and diffuse large B-cell lymphoma: Double expressor and triple expressor DLBCL cases were then analyzed, and the results showed that the case with MYC-positive/BCL2-positive is significantly inferior only in three-year OS compared with all others (0% vs 53%; p = 0.020) (Fig 4) but not in three-year PFS.